Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Mysimba

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Naltrexon Testmiljö

Naltrexon

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.

  2. Folkhälsan i Sverige Årsrapport 2014. Folkhalsomyndigheten [www]. [updated 2015-12-28, cited 2016-04-19].

  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - VIVTROL (naltrexone). Food and Drug Administration [www]. [updated 2006-04-13, cited 2016-04-01].

  4. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-25.

  5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-17.

  6. Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34:1803-12.

  7. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-62.

  8. Morley KC, Teesson M, Sannibale C, Baillie A, Haber PS. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial. Alcohol Alcohol. 2010;45:520-6.

  9. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-9.

  10. Kiefer F, Jahn H, Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry. 2005;38:184-6.

  11. Setiawan E, Pihl RO, Cox SM, Gianoulakis C, Palmour RM, Benkelfat C et al. The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res. 2011;35:1134-41.

  12. NALTREXONE (naltrexonhydroklorid). Summary of Product Characteristics. Medical Products Agency (MPA); 2014.

  13. Food and Drug Administration (FDA). Labeling - NALTREXONE HYDROCHLORIDE (naltrexone hydrochloride). Food and Drug Administration [www]. [updated 2016-04-12, cited 2016-04-01].

  14. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-13.

  15. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012;1:CD006219.

  16. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32:630-6.

  17. King AC, Cao D, Zhang L, O'Malley SS. Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry. 2013;73:924-30.

  18. Fonsi Elbreder M, de Souza e Silva R, Pillon SC, Laranjeira R. Alcohol dependence: analysis of factors associated with retention of patients in outpatient treatment. Alcohol Alcohol. 2011;46:74-6.

  19. Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61:392-8.

  20. Socialstyrelsens statistikdatabas . Stockholm: Socialstyrelsen. 2014 [cited 2016-02-17.]

  1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.
  2. Folkhälsan i Sverige Årsrapport 2014. Folkhalsomyndigheten [www]. [updated 2015-12-28, cited 2016-04-19].
  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - VIVTROL (naltrexone). Food and Drug Administration [www]. [updated 2006-04-13, cited 2016-04-01].
  4. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617-25.
  5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-17.
  6. Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34:1803-12.
  7. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-62.
  8. Morley KC, Teesson M, Sannibale C, Baillie A, Haber PS. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial. Alcohol Alcohol. 2010;45:520-6.
  9. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-9.
  10. Kiefer F, Jahn H, Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry. 2005;38:184-6.
  11. Setiawan E, Pihl RO, Cox SM, Gianoulakis C, Palmour RM, Benkelfat C et al. The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res. 2011;35:1134-41.
  12. NALTREXONE (naltrexonhydroklorid). Summary of Product Characteristics. Medical Products Agency (MPA); 2014.
  13. Food and Drug Administration (FDA). Labeling - NALTREXONE HYDROCHLORIDE (naltrexone hydrochloride). Food and Drug Administration [www]. [updated 2016-04-12, cited 2016-04-01].
  14. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-13.
  15. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012;1:CD006219.
  16. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, deWit H et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32:630-6.
  17. King AC, Cao D, Zhang L, O'Malley SS. Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry. 2013;73:924-30.
  18. Fonsi Elbreder M, de Souza e Silva R, Pillon SC, Laranjeira R. Alcohol dependence: analysis of factors associated with retention of patients in outpatient treatment. Alcohol Alcohol. 2011;46:74-6.
  19. Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61:392-8.
  20. Socialstyrelsens statistikdatabas . Stockholm: Socialstyrelsen. 2014 [cited 2016-02-17.]
C C
C C

Bupropion Testmiljö

Bupropion

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Manns A, Torregrossa H, Mahdjoub S, Gomajee R, Melchior M, El-Khoury Lesueur F. Do Determinants of Smoking Cessation and Relapse Differ between Men and Women? Data from a French National Study. Subst Use Misuse. 2024;59(2):167-176.

  2. Swan GE, Javitz HS, Jack LM, Curry SJ, McAfee T. Heterogeneity in 12-month outcome among female and male smokers. Addiction. 2004;99:237-50.

  3. Kuo CW, Lin CF, Chen CY, Wang RH, Chou CY, Cheng HJ et al. Body-Weight Gain in Women During Smoking Cessation Is a Sex-Specific Predictor of 6-Month Abstinence: A Retrospective Cohort Study. Front Public Health. 2022;10:872220.

  4. Cropsey KL, Leventhal AM, Stevens EN, Trent LR, Clark CB, Lahti AC et al. Expectancies for the effectiveness of different tobacco interventions account for racial and gender differences in motivation to quit and abstinence self-efficacy. Nicotine Tob Res. 2014;16:1174-82.

  5. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].

  6. LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140-154.

  7. Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18(4):447-457.

  8. Kerber CS, Dyck MJ, Culp KR, Buckwalter K. Antidepressant treatment of depression in rural nursing home residents. Issues Ment Health Nurs. 2008;29(9):959-73.

  9. Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological Sex Differences in Depression: A Systematic Review. Biol Res Nurs. 2018;20(4):383-392.

  10. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997;37:737-43.

  11. Martindale: The Complete Drug Reference. Pharmaceutical Press.

  12. Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol. 2001;41:770-8.

  13. Wellbutrin SR (bupropion). DailyMed [www]. [updated 2024-04-22, cited 2024-05-23].

  14. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906-22.

  15. Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD et al. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Drug Metab Dispos. 2013;41(3):575-81.

  16. Zyban (bupropion). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-04-04, citeid 2024-05-23].

  17. Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res. 2004;6:27-37.

  18. Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009;104:1043-52.

  19. Hoving EF, Mudde AN, de Vries H. Predictors of smoking relapse in a sample of Dutch adult smokers; the roles of gender and action plans. Addict Behav. 2006;31:1177-89.

  20. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70:522-33.

  21. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.

  22. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction. 2004;99:1206-18.

  23. Japuntich SJ, Leventhal AM, Piper ME, Bolt DM, Roberts LJ, Fiore MC et al. Smoker characteristics and smoking-cessation milestones. Am J Prev Med. 2011;40:286-94.

  24. Iliceto P, Fino E, Pasquariello S, D'Angelo Di Paola ME, Enea D. Predictors of success in smoking cessation among Italian adults motivated to quit. J Subst Abuse Treat. ;44:534-40.

  25. Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry. 2014;171:1199-205.

  26. Papakostas GI, Kornstein SG, Clayton AH, Soares CN, Hallett LA, Krishen A et al. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol. 2007;22(4):226-9.

  27. Liu X, Li R, Lanza ST, Vasilenko SA, Piper M. Understanding the role of cessation fatigue in the smoking cessation process. Drug Alcohol Depend. 2013;133:548-55.

  28. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.

  29. Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176.

  30. Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, Fix BV et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2013;108:193-202.

  31. Cooper J, Borland R, Yong HH. Australian smokers increasingly use help to quit, but number of attempts remains stable: findings from the International Tobacco Control Study 2002-09. Aust N Z J Public Health. 2011;35:368-76.

  32. Huang Y, Britton J, Hubbard R, Lewis S. Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob Control. 2013;22:274-9.

  33. Kotz D, Fidler J, West R. Factors associated with the use of aids to cessation in English smokers. Addiction. 2009;104:1403-10.

  34. Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ. 2013;347:f5704.

  35. Schwalsberger K, Reininghaus B, Reiter A, Dalkner N, Fleischmann E, Fellendorf F et al. Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?. Psychiatr Danub. 2022;34(2):219-228.

  36. Seifert J, Führmann F, Reinhard MA, Engel RR, Bernegger X, Bleich S et al. Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017. J Neural Transm (Vienna). 2021;128(6):827-843.

  37. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Manns A, Torregrossa H, Mahdjoub S, Gomajee R, Melchior M, El-Khoury Lesueur F. Do Determinants of Smoking Cessation and Relapse Differ between Men and Women? Data from a French National Study. Subst Use Misuse. 2024;59(2):167-176.
  2. Swan GE, Javitz HS, Jack LM, Curry SJ, McAfee T. Heterogeneity in 12-month outcome among female and male smokers. Addiction. 2004;99:237-50.
  3. Kuo CW, Lin CF, Chen CY, Wang RH, Chou CY, Cheng HJ et al. Body-Weight Gain in Women During Smoking Cessation Is a Sex-Specific Predictor of 6-Month Abstinence: A Retrospective Cohort Study. Front Public Health. 2022;10:872220.
  4. Cropsey KL, Leventhal AM, Stevens EN, Trent LR, Clark CB, Lahti AC et al. Expectancies for the effectiveness of different tobacco interventions account for racial and gender differences in motivation to quit and abstinence self-efficacy. Nicotine Tob Res. 2014;16:1174-82.
  5. Nationella riktlinjer för vård vid depression och ångestsyndrom 2021. Socialstyrelsen [www]. Socialstyrelsen. [updated 2021-04-01, cited 2021-05-14].
  6. LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44(1):140-154.
  7. Sramek JJ, Murphy MF, Cutler NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci. 2016;18(4):447-457.
  8. Kerber CS, Dyck MJ, Culp KR, Buckwalter K. Antidepressant treatment of depression in rural nursing home residents. Issues Ment Health Nurs. 2008;29(9):959-73.
  9. Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological Sex Differences in Depression: A Systematic Review. Biol Res Nurs. 2018;20(4):383-392.
  10. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997;37:737-43.
  11. Martindale: The Complete Drug Reference. Pharmaceutical Press.
  12. Stewart JJ, Berkel HJ, Parish RC, Simar MR, Syed A, Bocchini JA et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol. 2001;41:770-8.
  13. Wellbutrin SR (bupropion). DailyMed [www]. [updated 2024-04-22, cited 2024-05-23].
  14. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307(3):906-22.
  15. Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD et al. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Drug Metab Dispos. 2013;41(3):575-81.
  16. Zyban (bupropion). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-04-04, citeid 2024-05-23].
  17. Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res. 2004;6:27-37.
  18. Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. Addiction. 2009;104:1043-52.
  19. Hoving EF, Mudde AN, de Vries H. Predictors of smoking relapse in a sample of Dutch adult smokers; the roles of gender and action plans. Addict Behav. 2006;31:1177-89.
  20. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70:522-33.
  21. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
  22. Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction. 2004;99:1206-18.
  23. Japuntich SJ, Leventhal AM, Piper ME, Bolt DM, Roberts LJ, Fiore MC et al. Smoker characteristics and smoking-cessation milestones. Am J Prev Med. 2011;40:286-94.
  24. Iliceto P, Fino E, Pasquariello S, D'Angelo Di Paola ME, Enea D. Predictors of success in smoking cessation among Italian adults motivated to quit. J Subst Abuse Treat. ;44:534-40.
  25. Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry. 2014;171:1199-205.
  26. Papakostas GI, Kornstein SG, Clayton AH, Soares CN, Hallett LA, Krishen A et al. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol. 2007;22(4):226-9.
  27. Liu X, Li R, Lanza ST, Vasilenko SA, Piper M. Understanding the role of cessation fatigue in the smoking cessation process. Drug Alcohol Depend. 2013;133:548-55.
  28. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805.
  29. Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176.
  30. Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, Fix BV et al. Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction. 2013;108:193-202.
  31. Cooper J, Borland R, Yong HH. Australian smokers increasingly use help to quit, but number of attempts remains stable: findings from the International Tobacco Control Study 2002-09. Aust N Z J Public Health. 2011;35:368-76.
  32. Huang Y, Britton J, Hubbard R, Lewis S. Who receives prescriptions for smoking cessation medications? An association rule mining analysis using a large primary care database. Tob Control. 2013;22:274-9.
  33. Kotz D, Fidler J, West R. Factors associated with the use of aids to cessation in English smokers. Addiction. 2009;104:1403-10.
  34. Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ. 2013;347:f5704.
  35. Schwalsberger K, Reininghaus B, Reiter A, Dalkner N, Fleischmann E, Fellendorf F et al. Sex-Related Differences in the Pharmacological Treatment of Major Depression - Are Women and Men Treated Differently?. Psychiatr Danub. 2022;34(2):219-228.
  36. Seifert J, Führmann F, Reinhard MA, Engel RR, Bernegger X, Bleich S et al. Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017. J Neural Transm (Vienna). 2021;128(6):827-843.
  37. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]